Kelun-Biotech to present Phase 3 sacituzumab tirumotecan data at ESMO 2026

Kelun-Biotech will present Phase 3 results for sacituzumab tirumotecan in metastatic NSCLC and advanced endometrial cancer at ESMO 2026 in Madrid on Oct. 25-26.